> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Neurotech Review Extension on Retinal Disease BLA
- URL: https://www.fdaweb.com/neurotech-review-extension-on-retinal-disease-bla/
- Published: 2024-11-08T12:00:00.000Z
- Updated: 2026-09-14T14:46:32.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158153

FDA has extended by three months its review of a Neurotech Pharmaceuticals BLA for NT-501 (revakinagene taroretcel) as a treatment for macular telangiectasia Type 2 (MacTel). The extension is needed to review additional data provided by the company in response to recent requests from the agency. The revised user fee review action target date is 3/18.

Macular telangiectasia or idiopathic juxtafoveal macular telangiectasia Type 2 is described as a rare neurodegenerative disease that leads to localized retinal degeneration and secondary alterations of the retinal vasculature. It typically affects both eyes and causes a gradual deterioration in central vision, the company says.

NT-501 uses the company’s encapsulated cell therapy delivery system to deliver CNTF, a potent neuroprotective protein that promotes the survival and maintenance of photoreceptors, for treating chronic retinal diseases, such as MacTel, the company says.